<DOC>
	<DOCNO>NCT03031301</DOCNO>
	<brief_summary>The study prospective , adaptive , multicenter , randomize , double-blind , Sham-controlled study , evaluate efficacy safety Vibrant Capsule relieve constipation subject functional constipation . Two arm assess : - Vibrant Capsule administer 5 time per week - Sham Capsule administer 5 time per week Subjects follow 2 week baseline period take Vibrant Capsule treatment period 8 week . Data report do electronic Case Report Form ( eCRF ) eDiary . Subjects ask refrain take medication supplement relieve constipation , entire study period . After 14 day run-in period , subject return eligibility re-assessed . Subjects train use base unit swallow first capsule site day baseline visit . They activate ingest rest capsule home , use base unit . Subjects instruct complete simple subject eDiary day throughout duration study . A final visit take place end 8 week treatment period . Subjects receive phone call least week subject compliance monitor 8 week study .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Vibrant Capsule Administered 5 Times Per Week</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>1 . Subjects age 22 year old 2 . Subjects Chronic Idiopathic Constipation ( CIC ) accord Rome III criterion experience relief symptom available therapy 3 . Subjects average &lt; 3 Spontaneous Bowel Movements ( SBM ) per week â‰¥1 SBM per week 4 . Normal colonoscopy perform within 10 year prior study participation , unless subject &lt; 50 year old without alarm sign and/or symptom 5 . Subject sign Informed Consent Form ( ICF ) 6 . Female subject must negative pregnancy test 1 . History complicated/obstructive diverticular disease 2 . History intestinal colonic obstruction , suspect intestinal obstruction . 3 . History significant gastrointestinal disorder , include form inflammatory bowel disease gastrointestinal malignancy ( celiac disease accept subject treated remission ) 4 . History gastroparesis 5 . Use following medication : Medications may affect intestinal motility , prokinetics , antidepressant , antiParkinsonian medication , opiate , opioids , calciumchannel blocker , aluminum/magnesium hydroxide With exception antidepressant , thyroid hormonal replacement therapy , subject stable dose least 3 month prior enrollment . 6 . Clinical evidence significant respiratory , cardiovascular , renal , hepatic , biliary , endocrine , psychiatric neurologic disease . 7 . Presence cardiac pacemaker gastric electrical stimulator . 8 . History , current eating disorder , anorexia , bulimia , compulsory overeating . 9 . Diagnosis megarectum colon , congenital anorectal malformation , clinically significant rectocele , history intestinal resection ( exception appendectomy , cholecystectomy inguinal hernia repair ) , history bariatric surgery evidence structural abnormality gastrointestinal tract might affect transit 10 . History Zenker 's diverticulum , dysphagia , Barrett 's esophagus , esophageal stricture achalasia 11 . Chronic use nonsteroidal antiinflammatory drug ( NSAIDs ) 12 . Subjects pelvic floor dysfunction/defecatory disorder 13 . Participation another clinical study within one month prior screen . 14 . Women pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>